BioSpace News Archive

Mallinckrodt plc, a global biopharmaceutical company, announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar® Gel in patients with refractory rheumatoid arthritis that did not adequately respond to standard-of-care therapies.

Iterum Therapeutics plc today reported financial results for the fourth quarter and year ended December 31, 2021.

Bluejay Diagnostics, Inc. today announced that Edwin “Ed” E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer.

Anavex Life Sciences Corp. announced that Anavex Management team will participate in the Rare Neurodevelopmental Disorders Panel at the Cantor Virtual Rare Disease Summit on Wednesday, March 30, 2022 at 11:00 AM ET.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its fourth quarter and full year ended December 31, 2021.

ASLAN Pharmaceuticals today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab.

Avera Health (Avera), and Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), today announced a strategic collaboration to advance comprehensive molecular profiling, enabling Avera Health’s providers and patients to benefit from data-driven insights that inform targeted cancer treatments.

miR Scientific, and Leonie Hill Capital, announced today the signing of a collaboration agreement to partner in the commercial launch of the award-winning miR Sentinel™ Prostate Cancer Test in Singapore and Southeast Asia.

Alphatec Holdings, Inc. announced that Pat Miles, Chairman and Chief Executive Officer, and Todd Koning, Chief Financial Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45am ET.

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new preclinical data on its NAV-001 antibody-drug conjugate (ADC) program at the 12th World ADC Conference in London, UK, on Wednesday, March 30th.